Form 4: Maze Therapeutics Exec Exercises, Sells Shares

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised 30,000 stock options and subsequently sold all acquired shares under a pre-arranged trading plan.

Summary

• Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc., executed transactions on March 10, 2026.
• Exercised 30,000 stock options at an exercise price of $10.42 per share.
• Immediately sold 29,652 shares of common stock at a weighted average price of $50.4454 per share, with prices ranging from $50.00 to $50.99.
• Also sold an additional 348 shares of common stock at a weighted average price of $51.015 per share, with prices ranging from $51.00 to $51.09.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
• Following these transactions, the reporting person beneficially owns 267,407 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. While it's an insider sale, it was pre-planned under a 10b5-1 plan, which mitigates negative sentiment, and the executive retains significant option holdings, indicating continued alignment with shareholder interests.

Positives

• The executive realized a significant gain by exercising options at $10.42 and selling shares at an average price over $50.
• The transaction was pre-planned under a Rule 10b5-1 plan, indicating a structured approach to equity management and reducing concerns about opportunistic insider trading.

Negatives

• The sale of all shares acquired from the option exercise could be interpreted as a reduction in direct equity exposure by a key executive, although mitigated by the pre-planned nature.

Future Outlook

The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a pre-determined strategy for managing equity holdings rather than a reaction to immediate market conditions. The remaining 267,407 stock options suggest continued long-term equity interest in the company by the executive.

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under Rule 10b5-1 plans, are common for executives managing their compensation and diversifying their portfolios. In the biotechnology sector, where executive compensation often includes substantial equity, such transactions are a routine part of an executive's financial planning and typically do not signal a change in company fundamentals.

Stakeholder Impact

• Shareholders: May observe a slight increase in shares available on the market due to the sale, but the pre-planned nature limits negative interpretation regarding the company's prospects.
• Employees: No direct impact on employees beyond general market perception.

Next Steps

• Continued vesting of remaining stock options according to the original schedule, subject to the reporting person's continued service to the Issuer.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction (exercise and sell-to-cover) by an executive. While it represents a sale of shares, the execution under a Rule 10b5-1 plan suggests it's part of a long-term compensation management strategy rather than a reaction to new material information. The executive also retains a substantial number of unexercised options. Therefore, this specific filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation, as it's a non-discretionary event.

Keywords

Maze Therapeutics, MAZE, Harold Bernstein, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1, Executive Compensation, Biotechnology